StreetInsider.com News Articles

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

KRAKÓW, Poland, May 21, 2026 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading Drug Discovery and Development organizations in Europe, has published its financial results for Q1 2026 and latest backlog. The Company has decided to launch a strategic options review for the Group's further development and to maximize long-term shareholder value.

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports Q1 2026 results and launches strategic options review

Thu, 21 May 2026 01:13:00 -0400

The Group's operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin⁽¹⁾ reached 14%, compared to the estimated

Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024

Tue, 24 Sep 2024 02:04:00 -0400

KRAKÓW, Poland, Sept. 24, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published its financial results for Q2 2024, earnings estimates for Q3 204 and backlog for 2024 and 2025.

Financial and Operational Highlights

Selvita reports revenue growth in each subsequent quarter of 2024. In Q2 2024, commercial revenues were 6% higher than in Q1. Published estimates for Q3 suggest the rebound will continue, with the company expecting to generate between EUR 20.2 million and EUR 20.6 million in organic

Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024

Tue, 24 Sep 2024 02:04:00 -0400

Financial and Operational Highlights

Selvita reports revenue growth in each subsequent quarter of 2024. In Q2 2024, commercial revenues were 6% higher than in Q1. Published estimates for Q3 suggest the rebound will continue, with the company expecting to generate between EUR 20.2 million and EUR 20.6 million in organic

Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024

Tue, 24 Sep 2024 02:04:00 -0400

Financial and Operational Highlights

Selvita reports revenue growth in each subsequent quarter of 2024. In Q2 2024, commercial revenues were 6% higher than in Q1. Published estimates for Q3 suggest the rebound will continue, with the company expecting to generate between EUR 20.2 million and EUR 20.6 million in organic

Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024

Tue, 24 Sep 2024 02:04:00 -0400

Financial and Operational Highlights

Selvita reports revenue growth in each subsequent quarter of 2024. In Q2 2024, commercial revenues were 6% higher than in Q1. Published estimates for Q3 suggest the rebound will continue, with the company expecting to generate between EUR 20.2 million and EUR 20.6 million in organic

Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024

Tue, 24 Sep 2024 02:04:00 -0400

Financial and Operational Highlights

Selvita reports revenue growth in each subsequent quarter of 2024. In Q2 2024, commercial revenues were 6% higher than in Q1. Published estimates for Q3 suggest the rebound will continue, with the company expecting to generate between EUR 20.2 million and EUR 20.6 million in organic

Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024

Tue, 24 Sep 2024 02:04:00 -0400

Financial and Operational Highlights

Selvita reports revenue growth in each subsequent quarter of 2024. In Q2 2024, commercial revenues were 6% higher than in Q1. Published estimates for Q3 suggest the rebound will continue, with the company expecting to generate between EUR 20.2 million and EUR 20.6 million in organic

Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024

Tue, 24 Sep 2024 02:04:00 -0400

Financial and Operational Highlights

Selvita reports revenue growth in each subsequent quarter of 2024. In Q2 2024, commercial revenues were 6% higher than in Q1. Published estimates for Q3 suggest the rebound will continue, with the company expecting to generate between EUR 20.2 million and EUR 20.6 million in organic